Matthews亚洲股利主动型ETF ADVE 深 沪

Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update

Kura Oncology reported strong Q3 2026 performance with KOMZIFTI net product revenue up 53% to $13.9M, new patient starts up 30%, and total prescriptions up 65%. KOMZIFTI maintained majority share in the R/R NPM1-m AML market. The company advanced ziftomenib into frontline AML and reached FDA alignment on a darlifarnib registrational study for HRAS-mutant salivary gland cancer. Financially, Kura has $492.1M in cash and secured up to $300M addition...

11-10 21:02

Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals

Lantheus Holdings welcomed CMS's final rule maintaining separate payment for advanced diagnostic imaging agents and confirming PYLARIFY TruVu's Transitional Pass-Through status through September 30, 2029. A permanent HCPCS code (A9613) for PYLARIFY TruVu became effective October 1, 2026, aiding billing and reimbursement. Amanda Morgan highlighted the rule's support for patient access to advanced imaging and innovative radiopharmaceuticals, emphas...

11-05 12:15

Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement

Rhythm Pharmaceuticals amended its global exclusive license agreement with LG Chem for bivamelagon, an MC4R agonist. The revised agreement lowers the royalty rate from low-to-mid-single digits to 1% on global net sales, with Rhythm paying LG Chem $350 million in fixed installments over four years. Rhythm secured a $750 million term-loan facility led by KKR’s HealthCare Royalty and Blackstone to support the agreement, commercialization, and R&D. T...

11-03 02:59

Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases

Revuforj, a first-in-class menin inhibitor, has been awarded the 2026 Prix Galien for its groundbreaking treatment of relapsed or refractory acute leukemias in adults and children. FDA-approved for NPM1m AML and KMT2A translocated acute leukemia, Revuforj addresses critical unmet needs in aggressive blood cancers. The Galien Foundation's prestigious award highlights its transformative impact on leukemia treatment, recognizing the collaborative ef...

10-30 13:01

BOXABL (NASDAQ: BXBL) Announces Workforce Housing Project at Sage Memorial Hospital in Arizona

Austin, Texas, United States, October 22nd, 2026, FinanceWire PAID ADVERTISEMEN...

10-23 00:20

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

Rhythm Pharmaceuticals announced it will host a live conference call on November 3, 2026, to discuss its third-quarter 2026 financial results and corporate updates. Additionally, David Meeker, M.D., CEO, will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference on November 9, and Hunter Smith, CFO, will join a fireside chat at the Stifel 2026 Healthcare Conference on November 11. Both events will be webcast live and a...

10-21 12:00

BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE

10-21 11:00

Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026

Cytokinetics announced additional data from the ACACIA-HCM trial, showing Aficamten improves exercise performance, safety, and efficacy in non-obstructive hypertrophic cardiomyopathy (nHCM). The study demonstrated significant improvements in the Boston Exercise Aggregate Physiologic Response Score (BEAP-RS) and health status metrics. Aficamten also showed clinical benefits in multiple domains, with a favorable safety profile. The company plans to...

10-12 20:00

BOXABL’s (NASDAQ: BXBL) Factory-Built Housing Strategy Targets Large US Supply Gap

Austin, Texas, United States, September 17th, 2026, FinanceWire PAID ADVERTISEM...

09-18 00:30